Remove Antibody Remove DNA Remove Protein Remove Radiology
article thumbnail

News from AACR 2024: Sunday’s highlights

Drug Discovery World

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins. ADC for treating solid tumours’ demonstrated Claudin 18.2-specific

In-Vivo 52
article thumbnail

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

The Pharma Data

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Exosome-Based Liquid Biopsy in Oncology.

article thumbnail

3 Newest COVID-19 Tests Authorized by the FDA

XTalks

Adding to the testing repertoire is the first T cell-based test that can detect previous infection, akin to antibody tests. The persistence of antibodies after both natural COVID-19 infection and vaccination continues to be an area of intense study. 1. First T-Cell Test from Adaptive Biotechnologies.

Protein 98
article thumbnail

COVID-19 Pandemic Coverage

XTalks

Moderna, for one, recently reported positive results in older adults between 56 and 71, as well as those 71 years of age and older, who reportedly mounted levels of neutralizing antibodies against the SARS-CoV-2 virus after two doses of its vaccine that were comparable to those seen in younger adults. Johnson & Johnson’s COVID-19 Vaccine.